Business

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

PALO ALTO, Calif., December 11, 2025--Evommune, Inc. (NYSE: EVMN) (the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.

U2Fx.comU2Fx.com
Dec 12, 2025 - 02:00
 0  17
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
PALO ALTO, Calif., December 11, 2025--Evommune, Inc. (NYSE: EVMN) (the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.
Read More

Tags:

Previous Article

AI Bubble Or Business Revolution? Essential Business Insights

Next Article

Open banking a boon for Mortgage Choice brokers

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

U2Fx.com
U2Fx.com

Related Posts

How tariffs have impacted NYC small business bottom line

How tariffs have impacted NYC small business bottom line

U2Fx.com Feb 21, 2026  0  12

Permit? Check! Kansas City tries to make life easier for small businesses during World Cup

Permit? Check! Kansas City tries to make life easier fo...

U2Fx.com Nov 24, 2025  0  12

More Mass. cannabis shops gave up licenses in the past year than in the previous seven

More Mass. cannabis shops gave up licenses in the past ...

U2Fx.com Oct 30, 2025  0  15